WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H407312
CAS#: 163769-88-8
Description: YM-90709 is an interleukin-5 receptor antagonist. YM-90709 inhibits the binding of IL-5 to its receptor on peripheral human eosinophils and butyric acid-treated eosinophilic HL-60 clone 15 cells, with IC50 values of 1.0 and 0.57 microM, respectively. In functional assays, YM-90709 inhibited IL-5-prolonged eosinophil survival with an IC50 value of 0.45 microM and did not affect the GM-CSF-prolonged eosinophil survival. Furthermore, YM-90709 inhibited the IL-5-induced but not GM-CSF-induced tyrosine phosphorylation of Janus kinase 2 (JAK2) in eosinophilic HL-60 clone 15 cells.
Hodoodo Cat#: H407312
Name: YM-90709
CAS#: 163769-88-8
Chemical Formula: C22H21N3O2
Exact Mass: 359.16
Molecular Weight: 359.429
Elemental Analysis: C, 73.52; H, 5.89; N, 11.69; O, 8.90
Synonym: YM-90709; YM 90709; YM90709.
IUPAC/Chemical Name: 2,3-dimethoxy-6,6-dimethyl-5,6-dihydrobenzo[7,8]indolizino[2,3-b]quinoxaline
InChi Key: HIXSPVQXXDULHS-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H21N3O2/c1-22(2)12-13-9-19(26-3)20(27-4)10-14(13)18-11-17-21(25(18)22)24-16-8-6-5-7-15(16)23-17/h5-11H,12H2,1-4H3
SMILES Code: CC(CC1=CC(OC)=C(OC)C=C12)(C)N3C2=CC4=NC5=CC=CC=C5N=C43
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 359.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Morokata T, Suzuki K, Ida K, Yamada T. Effect of a novel interleukin-5
receptor antagonist, YM-90709, on antigen-induced eosinophil infiltration into
the airway of BDF1 mice. Immunol Lett. 2005 Apr 15;98(1):161-5. Epub 2004 Nov 28.
PubMed PMID: 15790522.
2: Morokata T, Suzuki K, Ida K, Tsuchiyama H, Ishikawa J, Yamada T. Effect of a
novel interleukin-5 receptor antagonist, YM-90709
(2,3-dimethoxy-6,6-dimethyl-5,6-dihydrobenzo[7,8]indolizino[2,3-b]quinoxaline),
on antigen-induced airway inflammation in BN rats. Int Immunopharmacol. 2004
Jul;4(7):873-83. PubMed PMID: 15182727.
3: Morokata T, Ida K, Yamada T. Characterization of YM-90709 as a novel
antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor.
Int Immunopharmacol. 2002 Nov;2(12):1693-702. PubMed PMID: 12469943.